Expert: New Guidance May Demand Clinical Decision Support Software Re-Evaluation
Businesses should reevaluate the classification of their clinical decision software based on a new FDA guidance, Kyle Faget of Foley & Lardner LLP tells Medtech Insight.
You may also be interested in...
Petition Argues FDA’s CDS Software Guidance Violates The Law
CDS Coalition legal counsel Bradley Thompson broke down the citizen petition calling for the US FDA to rescind the Clinical Decision Software guidance based on legal and procedural violations.
Digital Health Regulations: A Year In Review
RQM’s Allison Komiyama and Kevin Go summarized up the year’s changes to digital health regulation and outlined what to expect in the coming year.
FDA Panel Recommends Against De Novo Classification For Genetic OUD Risk Test
The FDA Clinical Chemistry and Toxicology Devices Panel voted 11-2 that the risks of AvertD’s genetic test for opioid use disorder outweigh the product’s potential benefits as a diagnostic.